The U.S. Food & Drug Administration (FDA) has approved a new drug to treat mild cognitive impairment (MCI, which has been defined as memory issues that may be a precursor for dementia) and early-stage Alzheimer’s disease (AD). The drug, donanemab (Kisunla®), is similar to lecanemab (Leqembi®), which was approved in …
Read More